당뇨병 관리용 인공지능 시장 : 디바이스 유형, 기술, 최종사용자, 배포 모드, 유형, 컴포넌트별 - 세계 예측(2025-2032년)

The Artificial Intelligence in Diabetes Management Market is projected to grow by USD 9.04 billion at a CAGR of 31.57% by 2032.

A compelling introduction that contextualizes artificial intelligence as a strategic force reshaping diabetes care delivery pathways clinical practice and patient engagement

The clinical and commercial landscape for diabetes management is undergoing a rapid transformation driven by artificial intelligence, digital health integration, and novel device architectures. This introduction sets the stage for understanding how AI-enabled tools are moving from experimental pilots to mainstream clinical workflows, influencing care pathways, patient engagement, and system-level performance. It also frames the interplay between technology maturation, regulatory evolution, and shifting stakeholder expectations that together are shaping near-term adoption dynamics.

As stakeholders read on, they will find the report structured to highlight practical implications rather than purely theoretical advances. Clinicians and provider organizations must now evaluate how predictive analytics and decision support systems change point-of-care decision-making, while payers and administrators weigh the operational and financing implications of remote monitoring and closed loop solutions. Meanwhile, patients increasingly expect seamless, smartphone-driven experiences that reduce daily management burden and provide actionable insights. This introduction therefore positions AI not as a standalone innovation but as a force multiplier acting across devices, software, and care models, setting clear expectations for the subsequent sections that analyze transformative shifts, segmentation, regional dynamics, and actionable recommendations.

An authoritative analysis of the systemic shifts driven by AI and connected care that are redefining clinical practice models reimbursement design and patient expectations in diabetes management

The last few years have revealed transformative shifts in the diabetes management landscape as AI and connected devices converge to create new standards of care. Clinical teams are increasingly adopting continuous monitoring and algorithm-driven insulin delivery to reduce variability and personalize therapy; concomitantly, software platforms that aggregate physiological and behavioral data enable more proactive, preventive interventions. These shifts reflect an emergent ecosystem in which hardware advances, real-time analytics, and cloud-enabled workflows interact to produce higher-resolution insight into glycemic control and risk trajectories.

Moreover, regulatory frameworks and reimbursement policies are beginning to adapt to evidence of clinical benefit and operational value. As a result, vendor strategies have pivoted from selling standalone devices toward integrated solutions that combine sensors, algorithms, and care coordination services. Patient expectations are also evolving: convenience, interoperability with consumer devices, and transparent data-sharing modalities now influence product adoption. Collectively, these dynamics are accelerating the migration of diabetes management from episodic, clinic-centric care to continuous, data-driven modalities that emphasize prevention, personalization, and system-level efficiency.

A rigorous examination of how cumulative United States tariffs enacted in 2025 reshaped supply chains procurement strategies and product development priorities across the diabetes ecosystem

The imposition of cumulative United States tariffs in 2025 created a distinct set of stresses and strategic responses across the diabetes device and software supply chain. In the immediate term, tariffs increased input costs for imported components and finished devices, prompting manufacturers to re-evaluate sourcing strategies and to accelerate supply chain localization where feasible. The result has been a deliberate reassessment of supplier relationships and contractual terms, with procurement teams emphasizing dual sourcing, longer lead-time planning, and inventory resilience to mitigate exposure to ongoing trade policy volatility.

In parallel, product development and commercialization timelines experienced pressure as cost ceilings and margin expectations shifted. Some vendors absorbed incremental costs to preserve competitiveness, while others recalibrated pricing or deferred noncritical investments. For software-centric offerings, cloud hosting and cross-border data transfer arrangements required renewed legal and compliance scrutiny to ensure alignment with evolving trade and data policies. Over the medium term, tariffs acted as a catalyst for investment in domestic manufacturing capacity and for strategic partnerships that prioritize nearshoring, thereby strengthening regional supply networks and creating conditional opportunities for local suppliers and contract manufacturers to scale operations in response to demand.

Deep segmentation insights that integrate device form factors technology stacks end-user profiles deployment modalities disease subtypes and component priorities to reveal practical adoption levers

Segmentation insight requires a granular understanding of how device form factors, enabling technologies, user settings, deployment models, disease types, and component emphasis interact to influence adoption and clinical impact. From a device perspective, blood glucose meters remain relevant for self-monitoring and noninvasive use cases while more advanced continuous glucose monitoring systems and insulin delivery mechanisms support closed loop automation that reduces daily burden. Distinctions between intermittently scanned and real-time continuous monitors, and between patch and tubed pumps, drive different user experiences and integration requirements, while fully closed loop systems demand higher interoperability and regulatory assurance than hybrid configurations.

Technology choices matter because cloud computing options, decision support modules, machine learning approaches, mobile application platforms, and predictive analytics capabilities determine scalability and clinical utility. Public and private cloud architectures shape data governance and latency characteristics, while decision support functions range from alert generation to dosage recommendations. Machine learning implementations that use supervised, unsupervised, or reinforcement approaches will yield different validation needs and clinician acceptance pathways. End-user segmentation further clarifies where value accrues: clinics and diabetes centers prioritize workflow integration and specialist support, hospitals focus on inpatient and outpatient continuity, home care emphasizes remote and self-monitoring convenience, and research institutes demand flexible data access for hypothesis testing. Deployment modes-cloud-based versus on-premise-create trade-offs between scalability and control, with hybrid implementations increasingly common. Disease-type segmentation, including gestational care with trimester-specific needs, Type 1 adult and juvenile onset distinctions, and Type 2 insulin-dependent versus non-insulin-dependent cohorts, informs clinical protocols and device selection. Finally, the component-level split between hardware elements such as pumps and sensors and software capabilities like algorithms and user interfaces underscores where investment and regulatory oversight concentrate.

Comprehensive regional insights detailing how Americas Europe Middle East & Africa and Asia-Pacific dynamics influence adoption regulatory engagement and commercial strategy for diabetes solutions

Regional dynamics fundamentally shape adoption pathways, reimbursement approaches, and supply chain architecture across the diabetes management landscape. In the Americas, health systems demonstrate a strong appetite for value-based models and remote monitoring capabilities, driving payer interest in outcomes-oriented partnerships and in products that can demonstrate measurable patient-level improvements. North American regulatory clarity around medical device software has encouraged pilot deployments within integrated delivery networks, while commercial payer dynamics influence how solutions are packaged and reimbursed.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse care delivery contexts require adaptive market entry strategies that account for national reimbursement models, privacy standards, and infrastructure variability. Manufacturers seeking traction across this region must optimize for interoperability and localization, balancing centralized cloud architectures with on-premise or edge computing where bandwidth and data sovereignty concerns prevail. In the Asia-Pacific region, rapid technology adoption, high smartphone penetration, and increasing public investment in digital health create fertile ground for scalable AI-enabled solutions, yet market entrants must navigate varying clinical practice patterns, procurement rules, and localized expectations for affordability and after-sales support. Taken together, these regional nuances dictate differentiated commercial approaches, strategic partnerships, and regulatory engagement plans.

Strategic company-level insights that illuminate competitive positioning partnership models investment priorities and the capabilities that determine long-term leadership in AI-enabled diabetes care

The competitive landscape is defined by a mix of established medical device manufacturers expanding into software-enabled care, technology firms offering analytics and platform services, and nascent entrants focused on niche patient experiences or algorithmic innovation. Market leaders emphasize integrated portfolios that combine sensing hardware, cloud-based analytics, and clinician-facing decision support, while middleware providers concentrate on interoperability layers that connect disparate devices and electronic health records. Meanwhile, software-first companies differentiate through algorithmic sophistication and user interface design, targeting both consumer engagement and clinician workflow augmentation.

Investors and strategic partners are also influencing the trajectory of innovation by prioritizing companies that demonstrate robust clinical evidence, scalable deployment models, and clear pathways to reimbursement. Partnerships between device OEMs and cloud or analytics providers remain a dominant strategy to accelerate time-to-market and to broaden service offerings. For organizations assessing competitive positioning, attention should focus on product modularity, data governance practices, regulatory readiness, and the ability to demonstrate meaningful clinical outcomes in real-world settings.

Actionable recommendations for industry leaders to accelerate adoption build trust and create resilient commercial models that drive measurable clinical outcomes

Industry leaders should pursue a set of pragmatic actions to translate technological promise into measurable clinical and commercial outcomes. First, prioritize interoperability and open standards to ensure devices and analytics can integrate into diverse clinical workflows and electronic health records. This approach reduces friction for provider adoption and facilitates multi-vendor ecosystems that enhance patient choice. Second, invest in rigorous clinical validation that pairs algorithmic outputs with clinician adjudication and patient-reported outcomes to build trust and support reimbursement discussions. Such evidence is critical for transitioning pilots into standard care pathways.

Third, adopt supply chain resilience strategies that include dual sourcing, nearshoring where appropriate, and contractual flexibility to respond to trade-policy shifts. Fourth, design pricing and reimbursement models that align incentives across providers, payers, and patients, prioritizing value-based arrangements tied to demonstrable improvements in control and reduced acute events. Fifth, develop user-centered interfaces and mobile experiences that reduce cognitive load for patients and clinicians alike, ensuring adherence and sustained engagement. Finally, cultivate strategic partnerships across hardware, software, and clinical domains to accelerate innovation while mitigating execution risk.

A transparent mixed-methods research approach combining expert interviews literature synthesis and rigorous validation to produce actionable and reproducible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure robustness, triangulation, and practical relevance. Primary research consisted of in-depth interviews with clinicians, product leaders, procurement officers, and regulatory specialists, supplemented by expert roundtables that explored clinical adoption barriers and commercial pathways. Secondary research reviewed peer-reviewed literature, regulatory guidance, clinical trial registries, and company disclosures to contextualize primary findings and to identify prevailing technology trends and validation approaches.

Data synthesis employed thematic analysis for qualitative inputs and structured frameworks to assess technology readiness, interoperability, and business model viability. Where applicable, validation steps included cross-referencing interview insights with documented regulatory filings and publicly available clinical evidence. Ethical considerations were central to the methodology, with informed consent obtained from interview participants and careful anonymization applied where requested. The outcome is a research product that emphasizes reproducible reasoning, transparent assumptions, and evidence-based conclusions designed to inform strategic decisions without relying on undisclosed proprietary datasets.

A concise conclusion highlighting the imperative for coordinated action across clinical validation interoperability and commercial design to realize AI-driven diabetes care benefits

In conclusion, artificial intelligence and connected-device innovation are converging to create a fundamentally different model of diabetes care-one that emphasizes continuous monitoring, personalized insulin delivery, and data-driven decision support. Stakeholders who move proactively to align product design, clinical validation, and commercial models with evolving regulatory and reimbursement landscapes will capture early advantage. Conversely, organizations that treat AI as a feature rather than as an integral component of care pathways risk limited adoption and fragmented impact.

The path forward requires collaboration among device manufacturers, software vendors, clinicians, payers, and policy makers to ensure that technological advances translate into real-world clinical benefits. By leveraging interoperability, prioritizing robust evidence generation, and designing sustainable business models, the industry can accelerate the shift from reactive management to proactive, personalized diabetes care that improves outcomes and reduces system burden.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of continuous glucose monitoring data with AI predictive algorithms to personalize insulin dosing based on real-time lifestyle patterns
• 5.2. Deployment of machine learning models in wearable devices for early detection of hypoglycemic events among high-risk diabetic patients
• 5.3. Use of natural language processing in virtual health assistants to provide tailored dietary and medication advice for diabetic individuals
• 5.4. Development of federated learning frameworks to train AI diabetes management models across multiple institutions while preserving patient data privacy
• 5.5. Adoption of AI-driven smartphone applications for automated meal recognition and insulin bolus recommendations using computer vision techniques
• 5.6. Collaboration between pharma companies and tech firms to validate AI-enabled closed-loop insulin delivery systems in large-scale clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Diabetes Management Market, by Device Type

• 8.1. Blood Glucose Meter
  • 8.1.1. Non Invasive Bg Meter
  • 8.1.2. Smbg
• 8.2. Closed Loop System
  • 8.2.1. Fully Closed Loop
  • 8.2.2. Hybrid Closed Loop
• 8.3. Continuous Glucose Monitor
  • 8.3.1. Intermittently Scanned Cgm
  • 8.3.2. Real Time Cgm
• 8.4. Insulin Pump
  • 8.4.1. Patch Pump
  • 8.4.2. Tubed Pump

9. Artificial Intelligence in Diabetes Management Market, by Technology

• 9.1. Cloud Computing
  • 9.1.1. Private Cloud
  • 9.1.2. Public Cloud
• 9.2. Decision Support Systems
  • 9.2.1. Alert Generation
  • 9.2.2. Dose Recommendation
• 9.3. Machine Learning
  • 9.3.1. Reinforcement Learning
  • 9.3.2. Supervised Learning
  • 9.3.3. Unsupervised Learning
• 9.4. Mobile Applications
  • 9.4.1. Android
  • 9.4.2. Ios
• 9.5. Predictive Analytics
  • 9.5.1. Glucose Trend Prediction
  • 9.5.2. Risk Prediction

10. Artificial Intelligence in Diabetes Management Market, by End User

• 10.1. Clinic
  • 10.1.1. Diabetes Center
  • 10.1.2. General Clinic
• 10.2. Home Care
  • 10.2.1. Remote Monitoring
  • 10.2.2. Self Monitoring
• 10.3. Hospital
  • 10.3.1. Inpatient
  • 10.3.2. Outpatient
• 10.4. Research Institute
  • 10.4.1. Academic
  • 10.4.2. Private

11. Artificial Intelligence in Diabetes Management Market, by Deployment Mode

• 11.1. Cloud Based
  • 11.1.1. Hybrid Cloud
  • 11.1.2. Public Cloud
• 11.2. On Premise
  • 11.2.1. Edge Computing
  • 11.2.2. Server Based

12. Artificial Intelligence in Diabetes Management Market, by Type

• 12.1. Gestational
  • 12.1.1. First Trimester
  • 12.1.2. Second Trimester
  • 12.1.3. Third Trimester
• 12.2. Type 1
  • 12.2.1. Adult Onset
  • 12.2.2. Juvenile Onset
• 12.3. Type 2
  • 12.3.1. Insulin Dependent
  • 12.3.2. Non Insulin Dependent

13. Artificial Intelligence in Diabetes Management Market, by Component

• 13.1. Hardware
  • 13.1.1. Pumps
  • 13.1.2. Sensors
  • 13.1.3. Wearable Devices
• 13.2. Software
  • 13.2.1. Algorithms
  • 13.2.2. Data Management
  • 13.2.3. User Interface

14. Artificial Intelligence in Diabetes Management Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Artificial Intelligence in Diabetes Management Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Artificial Intelligence in Diabetes Management Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Medtronic plc
  • 17.3.2. Abbott Laboratories
  • 17.3.3. Dexcom, Inc.
  • 17.3.4. F. Hoffmann-La Roche Ltd
  • 17.3.5. Insulet Corporation
  • 17.3.6. Tandem Diabetes Care, Inc.
  • 17.3.7. Teladoc Health, Inc.
  • 17.3.8. Omada Health, Inc.
  • 17.3.9. Bigfoot Biomedical, Inc.
  • 17.3.10. Glooko Inc.